Rhythm Pharmaceuticals, Inc.

    Jurisdiction
    United States
    LEI
    529900JPNWXQ8DPLA551
    ISIN
    US76243J1051 (RYTM)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    46 / 100
    Even with peer group:
    47 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. Read full profile

    Fundamentals

    Net revenue
    €133.31M
    Gross margin
    89.2%
    EBIT
    -€151.35M
    EBIT margin
    -113.5%
    Net income
    -€157.28M
    Net margin
    -118.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €259.76M +94.9% -€112.16M -28.7%
    €469.51M +80.7% €45.97M -141.0%
    €806.58M +71.8% €297.56M +547.4%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Shulman Joseph Chief Technical Officer -17K $105.30 -$1.77M
    Shulman Joseph Chief Technical Officer -4.2K $100.07 -$419.09K
    Smith Hunter C Chief Financial Officer -28K $96.29 -$2.70M
    German Christopher Paul Corporate Controller & CAO -1.5K $95.00 -$142.50K
    Shulman Joseph Chief Technical Officer -4K $90.08 -$358.88K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 14K $747.51K -9K Sell

    Earnings Calls

    Latest earnings call: May 7, 2024 (Q1 2024)

    Add to watchlist

    Notifications